HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yumi Hakozaki Selected Research

TAS6417

11/2019TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yumi Hakozaki Research Topics

Disease

3Neoplasms (Cancer)
04/2022 - 12/2020
2Bites and Stings (Sting)
04/2022 - 01/2022
1Breast Neoplasms (Breast Cancer)
12/2020
1Lung Neoplasms (Lung Cancer)
11/2019

Drug/Important Bio-Agent (IBA)

2Immune Checkpoint InhibitorsIBA
04/2022 - 01/2022
1RNA (Ribonucleic Acid)IBA
04/2022
1Interferon Type IIBA
04/2022
1Therapeutic UsesIBA
01/2022
1Biological ProductsIBA
01/2022
1human ERBB2 proteinIBA
12/2020
1Proteins (Proteins, Gene)FDA Link
12/2020
1Biomarkers (Surrogate Marker)IBA
12/2020
1Tyrosine Kinase InhibitorsIBA
11/2019
1TAS6417IBA
11/2019
1AfatinibIBA
11/2019
1Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2019
1HM781-36BIBA
11/2019
1osimertinibIBA
11/2019

Therapy/Procedure

2Radiotherapy
04/2022 - 01/2022
2Therapeutics
01/2022 - 12/2020